Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

@inproceedings{Moorkens2016OvercomingBT,
  title={Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies},
  author={Evelien Moorkens and Clara Jonker-Exler and Isabelle Huys and Paul J Declerck and Steven Simoens and Arnold Vulto},
  booktitle={Front. Pharmacol.},
  year={2016}
}
BACKGROUND In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain healthcare expenses, biosimilars could be instrumental in reducing costs for medication and increasing patient access to treatment. OBJECTIVES The aim of this study is to identify and describe the… CONTINUE READING